Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prescribing extended adjuvant letrozole.

K Gelmon1

  • 1BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC Canada V5Z 1L3. kgelmon@bccancer.bc.ca

Breast (Edinburgh, Scotland)
|June 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

ESMO open·2024
Same author

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Whole-genome and transcriptome analysis enhances precision cancer treatment options.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same journal

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Breast (Edinburgh, Scotland)·2026
Same journal

Comment on comparator design in regional versus general anesthesia for ambulatory breast-conserving surgery.

Breast (Edinburgh, Scotland)·2026
Same journal

HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.

Breast (Edinburgh, Scotland)·2026
Same journal

Patient satisfaction following Goldilocks mastectomy in non-obese women: A pilot study.

Breast (Edinburgh, Scotland)·2026
Same journal

Concerns about anesthetic standardization and interpretability in the comparison of regional anesthesia with dexmedetomidine versus general anesthesia.

Breast (Edinburgh, Scotland)·2026
Same journal

Translating CLEOPATRA into routine practice: National treatment patterns and survival for patients with HER2-positive metastatic breast cancer.

Breast (Edinburgh, Scotland)·2026
See all related articles

Extended adjuvant letrozole therapy for breast cancer patients after tamoxifen significantly improves disease-free survival. Longer treatment durations up to four years demonstrate ongoing safety and clinical benefit in postmenopausal women.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Adjuvant tamoxifen (5 years) is effective for breast cancer recurrence prevention, but residual risk remains.
  • Limited treatment options exist post-tamoxifen therapy for disease-free patients.
  • Aromatase inhibitors, like letrozole, are explored as extended adjuvant therapies.

Purpose of the Study:

  • To evaluate the efficacy and safety of extended adjuvant letrozole therapy.
  • To assess letrozole's benefit in postmenopausal women after completing tamoxifen.
  • To determine the optimal duration for extended adjuvant letrozole treatment.

Main Methods:

  • The MA-17 trial investigated letrozole versus placebo in postmenopausal women.
  • The trial was unblinded early due to demonstrated efficacy of letrozole.

Related Experiment Videos

  • Cohort analysis examined long-term outcomes with extended letrozole use.

    • Main Results:

    • Letrozole significantly improved disease-free survival compared to placebo.
    • Extended adjuvant letrozole therapy up to four years showed increasing benefits.
    • Longer treatment durations were found to be safe and clinically advantageous.

    Conclusions:

    • Extended adjuvant letrozole is effective in postmenopausal women after tamoxifen.
    • Up to four years of letrozole therapy provides ongoing disease-free survival benefits.
    • Longer durations of extended adjuvant letrozole are safe and clinically beneficial for breast cancer patients.